Here's Why You Should Retain Edward Lifesciences (EW) for Now

Edwards Lifesciences Corporation (EW) is well poised for growth in coming quarters, backed by the strength of a differentiated portfolio of advanced therapies. The company continues to witness strong performance of its SAPIEN 3 Ultra RESILIA platform, the leading platform in the United States and Japan. However, stiff rivalry and foreign exchange headwinds are a concern for EW's business. In the past six months, this Zacks Rank #3 (Hold) stock has gained 30.2% compared with an 18.1% rise of the industry and ...